These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 10950468)

  • 21. Antipsychotic medication: clinical guidelines for maintenance therapy.
    Johnson DA
    J Clin Psychiatry; 1985 May; 46(5 Pt 2):6-15. PubMed ID: 2859281
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Patient modified medication: how do schizophrenic patients manage their neuroleptics?].
    Hornung WP; Buchkremer G; Redbrake M; Klingberg S
    Nervenarzt; 1993 Jul; 64(7):434-9. PubMed ID: 8103569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia.
    Krausz M; Moritz S; Lambert M; Naber D
    Int Clin Psychopharmacol; 2000 Mar; 15(2):77-81. PubMed ID: 10759338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HLA antigens and neuroleptic response in clinical subtypes of schizophrenia.
    Bersani G; Valeri M; Bersani I; Piazza A; Adorno D; Casciani CU; Ciani N
    J Psychiatr Res; 1989; 23(3-4):213-20. PubMed ID: 2576825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS; Faraone SV; Brown WA
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study.
    Birur B; Thirthalli J; Janakiramaiah N; Shelton RC; Gangadhar BN
    Asian J Psychiatr; 2016 Dec; 24():17-22. PubMed ID: 27931900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased blink rates in schizophrenics. Influences of neuroleptics and psychopathology.
    Mackert A; Flechtner KM; Woyth C; Frick K
    Schizophr Res; 1991; 4(1):41-7. PubMed ID: 1672606
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative doses and costs of antipsychotic medication.
    Davis JM
    Arch Gen Psychiatry; 1976 Jul; 33(7):858-61. PubMed ID: 8024
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.
    Müller MJ; Wetzel H; Eich FX; Rein W; Puech A; Benkert O;
    J Clin Psychopharmacol; 2002 Dec; 22(6):554-60. PubMed ID: 12454554
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.
    Howanitz E; Pardo M; Smelson DA; Engelhart C; Eisenstein N; Stern RG; Losonczy MF
    J Clin Psychiatry; 1999 Jan; 60(1):41-4. PubMed ID: 10074877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A decision analysis approach to neuroleptic dosing: insights from a mathematical model.
    Mossman D
    J Clin Psychiatry; 1997 Feb; 58(2):66-73. PubMed ID: 9062375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study of the clinical utility of radioreceptor assay in outpatients with schizophrenia receiving high doses of neuroleptics.
    Gagné MA; Cormier H; Leblanc G; Lévesque D; Di Paolo T
    Can J Psychiatry; 1993 Oct; 38(8):534-40. PubMed ID: 7902199
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuroleptic dosing in chronic schizophrenia: a 10-year follow-up.
    Remington GJ; Prendergast P; Bezchlibnyk-Butler KZ
    Can J Psychiatry; 1997 Feb; 42(1):53-7. PubMed ID: 9040924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Negative symptoms and neuroleptics in catatonic schizophrenia.
    Salokangas RK; Honkonen T; Stengård E; Koivisto AM; Hietala J
    Schizophr Res; 2003 Jan; 59(1):73-6. PubMed ID: 12413645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroleptic dosing and neuroleptic plasma levels in schizophrenia: determining the optimal regimen.
    Shriqui CL
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S38-48. PubMed ID: 8564916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables.
    Naber D
    Int Clin Psychopharmacol; 1995 Sep; 10 Suppl 3():133-8. PubMed ID: 8866775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine.
    Litman RE; Su TP; Potter WZ; Hong WW; Pickar D
    Br J Psychiatry; 1996 May; 168(5):571-9. PubMed ID: 8733795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between neuroleptic dosage and cognitive functioning in chronic schizophrenic patients.
    Hansen M; Paredes J; Koczapski A; Ledwidge B; Kogan C
    Clin Invest Med; 1987 Sep; 10(5):368-71. PubMed ID: 2890458
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electroconvulsive therapy in neuroleptic-induced parkinsonism.
    Goswami U; Dutta S; Kuruvilla K; Papp E; Perenyi A
    Biol Psychiatry; 1989 Jul; 26(3):234-8. PubMed ID: 2568133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.